DVA News and Press, DaVita Inc. From 04/18/22

Pharmaceuticals and biotechnology still are attractive regarding value and quality. Other subsectors are overvalued by 15% to 42% relative to 11-year averages. Fast facts on IBB. 10 healthcare stocks cheaper than their peers in April. For further details see: IBB: He...

A jury acquitted the Denver, Colorado-based dialysis giant DaVita (NYSE:DVA) and its former Chief Executive Kent Thiry on charges that they conspired with three competitors not to recruit certain employees from each other in violation of federal labor laws. In a first-of-its-kind prosecu...

Are penny stocks worth it? These cheap stocks can become huge moneymakers if you understand how to handle volatile trading and manage risk. According to the definition of penny stocks, we’re talking about shares trading for $5 or less, and the lower the price, the higher the inherent...

Rockwell Medical Expands Partnership with DaVita PR Newswire $7.5M initial equity investment in Rockwell Amended and expanded supply agreement Strengthens Rockwell's financial position, laying groundwork for improved concentrate business WIX...

DaVita Announces Jason M. Hollar to Join its Board of Directors PR Newswire DENVER , April 7, 2022 /PRNewswire/ -- DaVita Inc . announced today that its board of directors appointed a new independent director, Jason M. Hollar , to join the board, ...

New Research Affirms Increase in Access, Equity of COVID-19 Vaccines Administered in Dialysis Centers PR Newswire Results demonstrate the importance of vaccinating patients at trusted sites of care DENVER and WALTHAM, Mass. , April 4, 2022 /PR...

Laboratory Corporation of America Holdings has exhibited some nice growth over the past few years, driven in large part by the pandemic. This makes the company look deceptively cheap, but when you dig in further, you find shares are still quite attractive. Long-term, this could ma...

Pharma/biotech is undervalued by about 14% relative to 11-year averages. Life science tools and healthcare equipment are overvalued by over 25%. Focus on IXJ: a more diversified alternative to XLV. 10 stocks cheaper than their peers in March. For further details see: ...

Glenview Capital Management’s 13F portfolio value decreased from $5.46B to $4.69B this quarter. The number of positions decreased from 59 to 57. They increased Global Payments and Coca Cola Euro Partners while dropping Paramount Global and Takeda. The top three stakes are T...

Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease - Company Acquires License to EA Pharma's Upacicalcet Worldwide Outside of Japan and Asia - - Industry Veteran Neal Fowler Named Chief Executive Officer of New Venture - ...